Brief: Alphamab Oncology Says License Agreement With 3D Medicines And Glenmark
25/01/2024 01:23
Jan 25 (Reuters) - Alphamab Oncology 9966.HK :
* LICENSE AGREEMENT WITH 3D MEDICINES AND GLENMARK FOR KN035
* JIANGSU ALPHAMAB AND 3D MEDICINES AND GLENMARK ENTERED
LICENSE
AGREEMENT
* AGREEMENT TO GRANT EXCLUSIVE LICENSE AND RIGHT TO
SUBLICENCE IN
RESPECT OF ONCOLOGY INDICATIONS OF KN035
Further company coverage: 9966.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alphamab Oncology
See all newsBrief: Alphamab Oncology Says Fei Wang Resigns As Chief Financial Officer
Brief: Alphamab Oncology Says First Patient Dosed In Phase III Clinical Study Of JSKN033 Monotherapy For Treatment Of Cervical Cancer
Brief: Alphamab Oncology Says Board Resolves To Repurchase Shares Up To HK$80 Million In Value
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab With HB1801 For Her2+ Advanced Breast Cancer
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab (KN026)